Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency
Learn more about:
Related Clinical Trial
A Phase 1, First-in-human Study of VX-668
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
A Phase 1, First-in-human Study of VX-634
A Phase I of OsrhAAT in Healthy Volunteers
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary Disease
A Study of Belcesiran in Patients With A1ATD-Associated Liver Disease
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiMZ Subjects
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals
COPD Exacerbation Blood and Urine Biomarkers Study
Alpha-1 Carrier Genomics Study
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
Study of ARO-AAT in Normal Adult Volunteers
Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home
AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry
Respreeza® Self-administration and Learning Program (AmAREtTI Study)
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
Alpha-1 Foundation DNA and Tissue Bank
Alpha1-antitrypsin Deficiency Registry
Alpha-1 Research Registry
Environment Effect on Six-Minute Walk Test Performance
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
Alpha-1 Coded Testing(ACT) Study
Long-Term Follow-up Study of ADVM-043
Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency
4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency
Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema
Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation”
EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin
GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency
Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency
Alpha-1 Foundation Research Registry
Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients
Evaluate Efficacy and Safety of “Kamada-AAT for Inhalation” in Patients With AATD
A Study of DCR-A1AT in Healthy Adult Volunteers and Patients With A1ATD-Associated Liver Disease
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients
Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency
Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 – Proteinase Inhibitor)
Aralast alpha1-proteinase Inhibitor Surveillance Study
Pharmacokinetic Study of ARALAST (Human Alpha1- PI)
The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency
Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency
Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency
Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency